Related Experiment Video

Updated: Jun 27, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Involvement of thioredoxin-binding protein 2 in the antitumor activity of CD437

Saori Matsuoka1, Hiroyuki Tsuchiya, Tomohiko Sakabe

  • 1Division of Molecular and Genetic Medicine, Graduate School of Medicine, Tottori University, Nishi-cho 86, Yonago, Tottori 683-8504, Japan.

Cancer Science
|November 21, 2008
PubMed

Insights

Synthetic retinoid CD437 triggers apoptosis in ovarian cancer cells by upregulating thioredoxin-binding protein 2 (TBP2). This mechanism involves calcium concentration and impacts the anti-apoptotic thioredoxin (TRX) pathway, highlighting TBP2

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Synthetic retinoids like CD437 induce apoptosis in ovarian adenocarcinoma cells, unlike natural retinoids.
  • The precise molecular mechanisms underlying CD437's pro-apoptotic effects remain incompletely understood.
  • Endoplasmic reticulum stress is implicated in CD437-induced apoptosis.

Purpose of the Study:

  • To elucidate the specific mechanism by which CD437 induces apoptosis in ovarian adenocarcinoma SKOV3 cells.
  • To investigate the role of thioredoxin-binding protein 2 (TBP2) in CD437-mediated apoptosis.

Main Methods:

  • Investigated the effect of CD437 on TBP2 expression in SKOV3 cells.
  • Assessed the role of intracellular calcium concentration in CD437-induced TBP2 upregulation.
  • Utilized small interfering RNA (siRNA) to block TBP2 induction and evaluated its impact on CD437 cytotoxicity.
  • Examined the interaction between TBP2, thioredoxin (TRX), and apoptosis signal-regulating kinase 1 (ASK1).

Main Results:

  • CD437 treatment led to the upregulation of TBP2 in SKOV3 cells, dependent on intracellular calcium levels.
  • CD437 induced the activation of ASK1 and c-Jun N-terminal kinase, downstream of TBP2.
  • CD437 promoted the association of TBP2 with TRX, leading to the dissociation of ASK1 from TRX.
  • Silencing TBP2 expression significantly reduced the cytotoxic effects of CD437.

Conclusions:

  • TBP2 upregulation plays a critical role in mediating the pro-apoptotic effects of CD437 in ovarian adenocarcinoma SKOV3 cells.
  • The mechanism involves calcium-dependent TBP2 induction, subsequent inhibition of TRX, and activation of the ASK1/c-Jun N-terminal kinase pathway.
  • These findings provide novel insights into the molecular pathways targeted by synthetic retinoids in ovarian cancer therapy.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...